TICKERNERD
Menu
AVXLAVXLHealthcare · Biotechnology

AVXL Stock Forecast: Anavex Life Sciences Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$3.22
−1.53% on the day

The 1 Wall Street analysts covering Anavex Life Sciences Corp. hold a median 12-month price target of $20 — +521.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$298.5M
Ticker Nerd rank
21 / 100
Median analyst target
$20
Analysts covering
1
Total return, dividends reinvested
1W
−3.6%
1M
+32.5%
YTD
−9.6%
1Y
−68.2%
From 52W high
−68.6%
From 52W low
+37.6%
$2
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVXL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anavex Life Sciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
74
Size
62
Quality
52
Issuance
43
Value
34
Volatility
28
Revisions
26
Accruals
23
Momentum
8

Growth (74): Sales and profits are climbing, and climbing faster than before.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVXL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVXL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26AVXLHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +521.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026D. Boral CapitalMaintainsBuy$24
26 Mar 2026D. Boral CapitalMaintainsBuy$24
23 Mar 2026D. Boral CapitalMaintainsBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
19 Dec 2025D. Boral CapitalMaintainsBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
28 Nov 2025HC Wainwright & Co.ReiteratesBuy—
26 Nov 2025D. Boral CapitalMaintainsBuy—
19 Nov 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
29 Oct 2025D. Boral CapitalMaintainsBuy—
24 Oct 2025Jones TradingDowngradeHold—
7 Oct 2025HC Wainwright & Co.ReiteratesBuy—
2 Oct 2025D. Boral CapitalMaintainsBuy—
1 Oct 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVXL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AVXL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Anavex Life Sciences Corp. (AVXL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.0×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
2.5×

Cheaper than 41% of US stocks

EV / EBITDA
−3.7×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−30.8%

Higher than 27% of US stocks

Return on assets
−19.5%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AVXL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVXLAnavex Life Sciences Corp.$298.5M
21
FATEFate Therapeutics, Inc.$298.8M
95
IFRXInflaRx NV$300.5M
9
IRDOpus Genetics, Inc.$293.8M
50
NMRANeumora Therapeutics, Inc.$291.3M
38
TRDAEntrada Therapeutics, Inc.$289.6M
51
VNDAVanda Pharmaceuticals, Inc.$308.5M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anavex Life Sciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVXL news & analysis

Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

GlobeNewsWire · 3 Aug 2026positive

Anavex Life Sciences announced plans to refresh its board of directors, nominating two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, who bring relevant life sciences experience.

Why it matters — AVXL watchers would care because adding independent directors with deep life sciences expertise could strengthen board oversight of the company's critical clinical and regulatory progress.

Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 30 July 2026neutral

Anavex Life Sciences reported preliminary financial results for its fiscal second quarter ended March 31, 2026, and provided a business update on the advancement of its lead compound ANAVEX®2-73 (blarcamesine) for early Alzheimer's disease, Rett syndrome, and Fragile X syndrome.

Why it matters — AVXL watchers would want to track the company's quarterly financial results and the progress of its lead clinical program for multiple CNS indications.

FAQ

Frequently asked questions about AVXL stock

What is the AVXL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Anavex Life Sciences Corp. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVXL stock a buy right now?

Of the 1 analysts covering Anavex Life Sciences Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anavex Life Sciences Corp. 21 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVXL?

As at 15 Aug 2026, Anavex Life Sciences Corp. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (74 of 100).

Will AVXL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +521.1% from the last close, and Ticker Nerd's factor model ranks Anavex Life Sciences Corp. 21 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVXL stock forecast for 2030?

No analyst covering Anavex Life Sciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has AVXL stock performed over the past year?

Anavex Life Sciences Corp. returned -68.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anavex Life Sciences Corp. do?

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

What is the latest news on AVXL?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation". Anavex Life Sciences announced plans to refresh its board of directors, nominating two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, who bring relevant life sciences experience.

Company

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. It focuses on precision medicine approaches, integrating clinical data, biomarkers, and genomic markers to target patient subgroups in central nervous system diseases. The company's lead candidate, ANAVEX 2-73 (blarcamesine), is an oral therapy that activates SIGMAR1 and muscarinic receptors to restore cellular homeostasis, supporting autophagy and addressing protein buildup in conditions like Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia. Another key program, ANAVEX 3-71, targets similar receptors and shows potential against cognitive deficits, amyloid, tau pathologies, mitochondrial dysfunction, and neuroinflammation. Anavex Life Sciences Corp. advances these investigational oral therapies through clinical trials, emphasizing biomarker-driven development for diseases with high unmet needs, including other CNS disorders, pain, and certain cancers. Headquartered in New York, New York, and founded in 2004, the company operates in the biotechnology sector, contributing to innovative treatments in brain health.

CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D. · 34 employees · United States · https://www.anavex.com